In the 1990s scientists found a way to genetically engineer T cells to recognize a specific cancer. These engineered T cells, called chimeric antigen receptor, or CAR, T cells, have been recently used as treatment for cancer, said Philip S. Low, Purdue's Ralph C. Corley Distinguished Profess...
作者: M.,Essand,A.,S.,I.,Loskog 摘要: T-cell immunotherapy is a promising approach to treat disseminated cancer. However, it has been limited by the ability to isolate and expand T cells restricted to tumour-associated antigens. Using ex vivo gene transfer, T cells from patients can ...
Nutrient metabolism shapes epigenetic landscape of T cells CD8+T cell exhaustion is defined by a unique transcriptional and epigenetic profile that is important to understand for the generation of immunotherapies to treat cancer. Research now shows how this profile can be regulated by T cells switchin...
[3]Luo T I,et al.Abstract CT069: Targeting EpCAM via CAR T-cells is an effective treatment for gastric cancer patients and subsequent toll-like receptor signaling activation in CD36+ monocyte underlies the resulting cyto...
H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006). Article CAS PubMed PubMed Central Google Scholar Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-...
In the current study, we sought to extend T cell therapy to the treatment of pancreatic cancer. However, a prerequisite step involved the identification of a target antigen which is present on the cell surface and is expressed or overexpressed on malignant cells, but has limited expression on ...
National Cancer Institute uses RetroNectin reagent to introduce T-cell receptor genes recognizing specific cancer antigens into a patient's own lymphocytes. These engineered cells are then returned to the patient, where they specifically target cancer cells expressing the antigen. That's Good Science!
T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCRengineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis...
[26] Puck J M. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia[J]. Immunol Rev, 2019, 287(1): 241-252. [27] Den Braber I, Mugwagwa T, Vrisekoop N, et al. Maintenance of peripheral naive T cells is s...
T cells have the capacity to eradicate diseased cells, but tumours present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost 'invisible' to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Ge...